These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 24745854)

  • 41. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
    Hart SN; Zhong XB
    Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.
    Fang J; Gorrod JW
    Cell Mol Neurobiol; 1999 Aug; 19(4):491-510. PubMed ID: 10379422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.
    Storelli F; Samer C; Reny JL; Desmeules J; Daali Y
    Clin Pharmacokinet; 2018 Oct; 57(10):1267-1293. PubMed ID: 29667038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.
    Bai JP
    Drug Metab Pharmacokinet; 2010; 25(1):62-71. PubMed ID: 20208389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome.
    Shakunthala N
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):1-15. PubMed ID: 19947890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
    Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Role of cytochrome P450 enzymes in pharmaceutical preparations].
    Baede van Dijk PA; de Graeff PA; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 1999 Dec; 143(52):2607-11. PubMed ID: 10633805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of pharmacogenetics of adverse drug reactions in elderly people.
    Cardelli M; Marchegiani F; Corsonello A; Lattanzio F; Provinciali M
    Drug Saf; 2012 Jan; 35 Suppl 1():3-20. PubMed ID: 23446782
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytochrome p450, part 1: what nurses really need to know.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):671-80. PubMed ID: 24295194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advocating for the Use of Pharmacogenomics: One Nurse's Story.
    Pestka EL; Shea CE
    J Psychosoc Nurs Ment Health Serv; 2016 Jul; 54(7):38-42. PubMed ID: 27362384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene-Based Dose Optimization in Children.
    Ramsey LB; Brown JT; Vear SI; Bishop JR; Van Driest SL
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():311-331. PubMed ID: 31283429
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
    Harvey AT; Preskorn SH
    J Clin Psychopharmacol; 1996 Oct; 16(5):345-55. PubMed ID: 8889906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Prevention of adverse drug reactions in older patients].
    Burkhardt H; Wehling M; Gladisch R
    Z Gerontol Geriatr; 2007 Aug; 40(4):241-54. PubMed ID: 17701115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?
    Tomlinson B; Hu M; Lee VW
    Mol Nutr Food Res; 2008 Jul; 52(7):799-809. PubMed ID: 18618477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adding pharmacogenetics to the clinical laboratory: narrow therapeutic index medications as a place to start.
    Bukaveckas BL
    Arch Pathol Lab Med; 2004 Dec; 128(12):1330-3. PubMed ID: 15578874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.